September 19, 2016 8:30am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management
will present at the Ladenburg Thalmann 2016 Healthcare Conference on
September 27th, 2016 at 10:30 AM (ET).
About OPKO Health
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes BioReference Laboratories, the
third-largest clinical laboratory in the U.S. with a core genetic
testing business and a 420-person sales force to drive growth and sell
new products, such as the 4Kscore® prostate cancer test and the Claros®
1 in office immunoassay platform. Our pharmaceutical business features
RAYALDEE®, an FDA-approved treatment for stage 3-4 CKD patients with
secondary hyperparathyroidism and vitamin D insufficiency, and VARUBI™
for chemotherapy-induced nausea and vomiting (oral formulation launched
by partner Tesaro and IV formulation PDUFA is January 2017). Our
biologics products under development are hGH-CTP, a once-weekly human
growth hormone for injection (partnered with Pfizer), long-acting Factor
VIIa for hemophilia (in Phase 2a) and a long-acting oxyntomodulin for
diabetes and obesity (in Phase 1). OPKO has production and distribution
assets in several countries abroad, strategic investments and an active
business development strategy. More information is available at www.opko.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005346/en/
OPKO Health, Inc.
Company
OPKO Health, Inc.
Tara
Mackay, 305-575-4100
Investor Relations
or
Media
Rooney
Partners
Terry Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
Investors
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released September 19, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page